Wall Street Radar: Auxilium Pharmaceuticals (AUXL), 22nd Century Group (XXII), Napco Security Technologies (NSSC), Rentrak (RENT)

Posted In Healthcare - By Matt Schrock On Friday, September 19th, 2014 With 0 Comments

Dallas, Texas 09/19/2014 (ustradevoice) – The approval of Stendra for use 15 minutes before sexual activity did not have the expected impact on the stock of Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL). The stock tumbled 0.19% in the regular session and almost 4% in the afterhours on Thursday. The FDA approved the erectile dysfunction drug for use 15 minutes before the activity down from 30 minutes. There were expectations that investors would love the news and send the shares of AUXL up. The drug was developed by Vivus Inc, but is marketed by Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) in the U.S. and Canada.

22nd Century Group Inc (NYSEMKT:XXII) said that is wholly-owned unit known as Botanical Genetics LLC, entered into an agreement with Anandia Laboratories that involves the acquisition of rights to an important cannabinoid production technologies. 22nd Century Group Inc (NYSEMKT:XXII) said the development gives its subsidiary, Botanical, competitive advantage in the emerging and promising cannabis technology. That agreement comes just a few days after 22nd Century Group Inc (NYSEMKT:XXII) announced a financing deal of about $10 million to bankroll its acquisitions and other projects.

Napco Security Technologies Inc (NASDAQ:NSSC) intends to return some value to its shareholders in the form of stock repurchase. The company announced that it would trim its 19.4 million outstanding shares by as many as a million. Napco Security Technologies Inc (NASDAQ:NSSC) is an $84.47 million company that provides security systems.

Rentrak Corporation (NASDAQ:RENT) was initiated at Wunderlich where the firm issued a “buy” recommendation on it and its target price hoisted at $75, which signals potential upside of 33.32%. Rentrak Corporation (NASDAQ:RENT) had a successful quarter in its 1Q2015. It earned $0.01 per share at a time when most analysts were expecting a loss of $0.11 per share for the quarter. Revenue for the quarter was up almost 36% to $22.70 million. Most analysts covering the stock are bullish about its prospects. Analysts at Needham & Company recently joined the bullish chorus and issued a “buy” rating and a target price of $64 on the stock.

About the Author

- Matt Schrock received Bachelor of Arts in Mass Media Communications from Penn State University.

Leave a comment

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>